Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 6/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 6/20 | 0.38 |
| ▸ | ATR | Q13535 | 7/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17033309 | 0.83 | CYP4F2 (0.46) | ALDH1A1LMNAPOLBRXRARXRB | |
| SCHEMBL30828321 | 0.81 | ALDH1A1 (0.44) | ALDH1A1LMNAPOLBRXRARXRB | |
| SCHEMBL23458850 | 0.81 | ALDH1A1 (0.44) | ALDH1A1LMNAPOLBRXRARXRB | |
| SCHEMBL30301952 | 0.81 | CYP4F2 (0.46) | ALDH1A1LMNAPOLBRXRARXRB | |
| SCHEMBL31358026 | 0.81 | ALDH1A1 (0.44) | ALDH1A1LMNAPOLBRXRARXRB | |
| SCHEMBL28811801 | 0.80 | ALDH1A1 (0.41) | ALDH1A1LMNAPOLBRXRARXRB | |
| SCHEMBL23481980 | 0.80 | ALDH1A1 (0.41) | ALDH1A1LMNAPOLBRXRARXRB | |
| SCHEMBL25832866 | 0.78 | LRRK2 (0.41) | — | |
| SCHEMBL19771084 | 0.78 | ALDH1A1 (0.38) | ALDH1A1LMNAPOLBRXRARXRB | |
| SCHEMBL24842264 | 0.77 | RXRA (0.41) | ALDH1A1LMNAPOLBRXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10464956-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-9758537-B2 | Compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758537-B2 | Compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS (US) | 2017-09-12 | — | — | US | disclosed |
| US-20150239838-A1 | Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239838-A1 | Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, CFH | ALDH1A1 2261/4885LMNA 1382/4885POLB 3581/4885 |
| US-10464956-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders | TFPI, CFD, F3 | ALDH1A1 1886/4885LMNA 1587/4885POLB 4443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.